Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Celsion	Lumos Pharma	Acasti Pharma	Rockwell Medical	Vascular Biogenics
Symbol	NASDAQ:CLSN	NASDAQ:LUMO	NASDAQ:ACST	NASDAQ:RMTI	NASDAQ:VBLT
Price Information
Current Price	$1.04	$9.89	$0.44	$0.92	$1.98
52 Week Range	Hold	Buy	Hold	Buy	Buy
MarketRank™
Overall Score	1.3	1.7	1.2	1.3	1.3
Analysis Score	3.0	3.5	3.2	3.5	3.5
Community Score	2.7	3.3	2.7	2.4	2.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.8	0.0	0.0	0.0
Earnings & Valuation Score	0.6	0.6	0.0	0.6	0.6
Analyst Ratings
Consensus Recommendation	Hold	Buy	Hold	Buy	Buy
Consensus Price Target	$4.00	$33.50	$2.98	$5.50	$4.67
% Upside from Price Target	284.62% upside	238.73% upside	582.34% upside	501.09% upside	135.69% upside
Trade Information
Market Cap	$90.02 million	$82.53 million	$90.85 million	$85.63 million	$95.41 million
Beta	2.42	1.69	2.45	1.11	1.17
Average Volume	14,149,298	53,475	32,321,547	1,937,791	917,883
Sales & Book Value
Annual Revenue	$500,000.00	$940,000.00	N/A	$61.30 million	$560,000.00
Price / Sales	180.04	87.80	N/A	1.40	170.38
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.63 per share	$19.03 per share	$0.14 per share	$0.32 per share	$1.00 per share
Price / Book	1.65	0.52	N/A	2.86	1.98
Profitability
Net Income	$-16,850,000.00	$-42,990,000.00	$-25,510,000.00	$-34,130,000.00	$-19,460,000.00
EPS	($0.91)	($9.27)	($0.23)	($0.56)	($0.54)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	∞	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-4,315.00%	-2,053.30%	N/A	-47.23%	-2,692.41%
Return on Equity (ROE)	-104.32%	-10.58%	-342.52%	-117.67%	-61.77%
Return on Assets (ROA)	-47.65%	-7.83%	-112.03%	-46.33%	-47.23%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.25%	N/A	N/A	0.50%	N/A
Current Ratio	3.67%	19.41%	3.66%	6.13%	5.16%
Quick Ratio	3.67%	19.40%	3.66%	5.83%	5.16%
Ownership Information
Institutional Ownership Percentage	13.73%	43.79%	1.12%	26.72%	4.50%
Insider Ownership Percentage	20.49%	15.90%	N/A	4.70%	N/A
Miscellaneous
Employees	27	28	32	300	38
Shares Outstanding	86.56 million	8.35 million	208.38 million	93.59 million	48.19 million
Next Earnings Date	8/13/2021 (Estimated)	8/12/2021 (Estimated)	7/5/2021 (Estimated)	5/17/2021 (Confirmed)	8/12/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	What Is The Ownership Structure Like For Vascular Biogenics Ltd. (NASDAQ:VBLT)? nasdaq.com - May 14 at 12:47 AM
	$300,000.00 in Sales Expected for Vascular Biogenics Ltd. (NASDAQ:VBLT) This Quarter americanbankingnews.com - May 13 at 2:34 AM
	Vascular Biogenics (NASDAQ:VBLT) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS americanbankingnews.com - May 12 at 12:10 PM
	Vascular Biogenics Ltd. (NASDAQ:VBLT) Expected to Announce Earnings of -$0.13 Per Share americanbankingnews.com - May 11 at 5:18 PM
	Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates finance.yahoo.com - May 11 at 1:19 PM
	Vascular Biogenics: Q1 Earnings Snapshot houstonchronicle.com - May 11 at 8:18 AM
	VBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update finance.yahoo.com - May 11 at 8:18 AM
	Vascular Biogenics's Earnings: A Preview benzinga.com - May 10 at 12:16 PM
	Vascular Biogenics (VBLT) to Release Earnings on Tuesday americanbankingnews.com - May 5 at 11:13 AM
	VBL Therapeutics to Report First Quarter Financial Results on May 11 finance.yahoo.com - May 4 at 7:39 AM
	Vascular Biogenics Ltd. [VBLT] is 19.58% higher this YTD. Is it still time to buy? dbtnews.com - May 3 at 10:08 AM
	Vascular Biogenics Ltd (VBLT) investing.com - April 30 at 1:48 PM
	Vascular Biogenics Ltd. (NASDAQ:VBLT)Metrics You Need to Know Right Now stocksregister.com - April 29 at 12:36 PM
	Vascular Biogenics Ltd. [VBLT] gain 13.76% so far this year. What now? dbtnews.com - April 29 at 12:36 PM
	Vascular Biogenics Ltd. (NASDAQ:VBLT) – Analysts See The Stock Differently Today marketingsentinel.com - April 28 at 3:37 PM
	Zacks: Analysts Anticipate Vascular Biogenics Ltd. (NASDAQ:VBLT) Will Post Quarterly Sales of $200,000.00 americanbankingnews.com - April 26 at 5:59 AM
	Vascular Biogenics Ltd. (NASDAQ:VBLT) Has Recovered 40.12% So Far, But Another 87.57% Gain Cannot Be Ruled Out marketingsentinel.com - April 18 at 9:06 AM
	Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants finance.yahoo.com - April 14 at 8:51 AM
	Vascular Biogenics Ltd. (NASDAQ:VBLT) surprises Wall Street with 10.98% stock price gain marketingsentinel.com - April 13 at 12:43 PM
	Vascular Biogenics Ltd. [VBLT] Stock trading around $1.73 per share: What’s Next? dbtnews.com - April 12 at 2:52 PM
	Does Vascular Biogenics Ltd. (NASDAQ:VBLT) Still Need To Convince Analysts? stocksregister.com - April 12 at 9:32 AM
	Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants finance.yahoo.com - April 9 at 1:21 PM
	Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded ... apnews.com - April 8 at 5:55 PM
	Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants finance.yahoo.com - April 8 at 5:55 PM
	VBL Therapeutics to Host Virtual R&D Day on April 6 finance.yahoo.com - March 30 at 7:54 AM

Date	Company	Brokerage	Action
7/16/2020	Celsion	Oppenheimer	Downgrade
7/13/2020	Celsion	Dawson James	Downgrade
7/25/2019	Celsion	Brookline Capital Management	Reiterated Rating
4/13/2021	Lumos Pharma	Jonestrading	Initiated Coverage
3/17/2021	Lumos Pharma	Stifel Nicolaus	Upgrade
12/2/2020	Lumos Pharma	Cantor Fitzgerald	Initiated Coverage
11/23/2020	Lumos Pharma	HC Wainwright	Boost Price Target
8/25/2020	Lumos Pharma	Piper Sandler	Initiated Coverage
8/17/2020	Lumos Pharma	Roth Capital	Reiterated Rating
4/16/2020	Lumos Pharma	Jefferies Financial Group	Initiated Coverage
9/2/2020	Acasti Pharma	Aegis	Downgrade
9/1/2020	Acasti Pharma	B. Riley	Lower Price Target
6/30/2020	Acasti Pharma	Echelon Wealth Partners	Reiterated Rating
7/18/2019	Acasti Pharma	CIBC	Initiated Coverage
11/11/2019	Rockwell Medical	Piper Jaffray Companies	Lower Price Target
6/19/2019	Rockwell Medical	Ifs Securities	Downgrade
12/10/2020	Vascular Biogenics	Chardan Capital	Reiterated Rating

(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources